* Gilead Sciences Inc., of Foster City, Calif., reported positive results from animal studies conducted by the U.S. Army Medical Research Institute of Infectious Diseases. Researchers found that the company's antiviral drug cidofovir prevented death and disease associated with poxvirus infection. In primates infected with monkeypox, cidofovir treatment reduced respiratory symptoms, fever and pox-like skin lesions, and decreased mortality associated with the viral infection. The data were presented at the International Conference on Emerging Infectious Disease, in Atlanta.

No Comments